Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1998 Apr 29

PMID 9557710

Citations 133

Authors

K Jooss

Y Yang

K J Fisher

J M Wilson

Affiliations

Soon will be listed here.

Abstract

Immune responses to vector-corrected cells have limited the application of gene therapy for treatment of chronic disorders such as inherited deficiency states. We have found that recombinant adeno-associated virus (AAV) efficiently transduces muscle fibers in vivo without activation of cellular and humoral immunity to neoantigenic transgene products such as beta-galactosidase, which differs from the experience with recombinant adenovirus, where vibrant T-cell responses to the transgene product destroy the targeted muscle fibers. T cells activated following intramuscular administration of adenovirus expressing lacZ (AdlacZ) can destroy AAVlacZ-transduced muscle fibers, indicating a prior state of immunologic nonresponsiveness in the context of AAV gene therapy. Adoptive transfer of dendritic cells infected with AdlacZ leads to immune mediated elimination of AAVlacZ-transduced muscle fibers. AAVlacZ-transduced antigen-presenting cells fail to demonstrate beta-galactosidase activity and are unable to elicit transgene immunity in adoptive transfer experiments. These studies indicate that vector-mediated transduction of dendritic cells is necessary for cellular immune responses to muscle gene therapy, a step which AAV avoids, providing a useful biological niche for its use in gene therapy.

Citing Articles

Adeno-Associated Viral Vectors in the Treatment of Epilepsy.

Mullagulova A, Timechko E, Solovyeva V, Yakimov A, Ibrahim A, Dmitrenko D Int J Mol Sci. 2024; 25(22).

PMID: 39596149 PMC: 11593886. DOI: 10.3390/ijms252212081.

Gene therapy of Dent disease type 1 in newborn ClC-5 null mice for sustained transgene expression and gene therapy effects.

Lyu P, Yadav M, Yoo K, Jiang C, Li Q, Atala A Gene Ther. 2024; 31(11-12):563-571.

PMID: 39322766 PMC: 11576508. DOI: 10.1038/s41434-024-00490-w.

Transcriptomic Analysis Reveals the Inability of Recombinant AAV8 to Activate Human Monocyte-Derived Dendritic Cells.

Masri S, Carre L, Jaulin N, Vandamme C, Couzinie C, Guy-Duche A Int J Mol Sci. 2023; 24(13).

PMID: 37445621 PMC: 10341499. DOI: 10.3390/ijms241310447.

Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation.

Ewaisha R, Anderson K Front Bioeng Biotechnol. 2023; 11:1138596.

PMID: 36873375 PMC: 9978118. DOI: 10.3389/fbioe.2023.1138596.

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.

Arjomandnejad M, Dasgupta I, Flotte T, Keeler A BioDrugs. 2023; 37(3):311-329.

PMID: 36862289 PMC: 9979149. DOI: 10.1007/s40259-023-00585-7.

References

Fu T, Ulmer J, Caulfield M, Deck R, Friedman A, Wang S . Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med. 1997; 3(6):362-71. PMC: 2230213. View

Goebels N, Michaelis D, Wekerle H, Hohlfeld R . Human myoblasts as antigen-presenting cells. J Immunol. 1992; 149(2):661-7. View

Xiao X, Li J, Samulski R . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996; 70(11):8098-108. PMC: 190884. DOI: 10.1128/JVI.70.11.8098-8108.1996. View

Hohlfeld R, Engel A . Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol. 1990; 136(3):503-8. PMC: 1877498. View

Fang B, Wang H, Gordon G, Bellinger D, Read M, Brinkhous K . Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 1996; 3(3):217-22. View

Fisher K, Gao G, Weitzman M, Dematteo R, Burda J, Wilson J . Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 1996; 70(1):520-32. PMC: 189840. DOI: 10.1128/JVI.70.1.520-532.1996. View

Flotte T, Afione S, Conrad C, McGrath S, Solow R, Oka H . Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A. 1993; 90(22):10613-7. PMC: 47827. DOI: 10.1073/pnas.90.22.10613. View

Yang Y, Li Q, Ertl H, Wilson J . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995; 69(4):2004-15. PMC: 188865. DOI: 10.1128/JVI.69.4.2004-2015.1995. View

van Ginkel F, Liu C, Simecka J, Dong J, Greenway T, Frizzell R . Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther. 1995; 6(7):895-903. DOI: 10.1089/hum.1995.6.7-895. View

10.

Tripathy S, BLACK H, GOLDWASSER E, Leiden J . Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996; 2(5):545-50. DOI: 10.1038/nm0596-545. View

11.

Whartenby K, Abboud C, J Marrogi A, Ramesh R, Freeman S . The biology of cancer gene therapy. Lab Invest. 1995; 72(2):131-45. View

12.

Fisher K, Jooss K, Alston J, Yang Y, Haecker S, High K . Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med. 1997; 3(3):306-12. DOI: 10.1038/nm0397-306. View

13.

Plautz G, Yang Z, Wu B, Gao X, Huang L, Nabel G . Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A. 1993; 90(10):4645-9. PMC: 46569. DOI: 10.1073/pnas.90.10.4645. View

14.

Descamps V, Duffour M, Mathieu M, Fernandez N, Cordier L, Abina M . Strategies for cancer gene therapy using adenoviral vectors. J Mol Med (Berl). 1996; 74(4):183-9. DOI: 10.1007/BF00204748. View

15.

Yang Y, Trinchieri G, Wilson J . Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med. 1995; 1(9):890-3. DOI: 10.1038/nm0995-890. View

16.

Yang Y, Jooss K, Su Q, Ertl H, Wilson J . Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 1996; 3(2):137-44. View

17.

Wilson J . Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest. 1995; 96(6):2547-54. PMC: 185958. DOI: 10.1172/JCI118318. View

18.

Miller J, Donahue R, Sellers S, Samulski R, Young N, Nienhuis A . Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci U S A. 1994; 91(21):10183-7. PMC: 44982. DOI: 10.1073/pnas.91.21.10183. View

19.

Armentano D, Zabner J, Sacks C, Sookdeo C, Smith M, St George J . Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol. 1997; 71(3):2408-16. PMC: 191351. DOI: 10.1128/JVI.71.3.2408-2416.1997. View

20.

Kaplitt M, Leone P, Samulski R, Xiao X, Pfaff D, OMalley K . Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994; 8(2):148-54. DOI: 10.1038/ng1094-148. View